Concert Pharmaceuticals Reports First Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/15/2026
- Wall St ends higher on cool inflation data, strong earnings
- U.S. headline producer inflation posts first one-month decrease since August 2025
- PayPal rallies 20% on report Stripe, Advent made $53 billion bid
- Oil prices make small gain on smaller US inventory draw
- ASML capacity upgrade soothes AI chip bottleneck fears
Concert Pharma (CNCE) Tops Q1 EPS by 2c
May 4, 2021 7:39 AM EDTConcert Pharma (NASDAQ: CNCE) reported Q1 EPS of ($0.67), $0.02 better than the analyst estimate of ($0.69).
We are committed to advancing CTP-543, our breakthrough therapy candidate for moderate to severe alopecia areata. Patients currently lack effective, approved treatment options. We believe we have the... More
